Waterloo Capital L.P. Sells 3,125 Shares of Agilent Technologies, Inc. (NYSE:A)

Waterloo Capital L.P. reduced its stake in Agilent Technologies, Inc. (NYSE:A) by 30.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,102 shares of the medical research company’s stock after selling 3,125 shares during the quarter. Waterloo Capital L.P.’s holdings in Agilent Technologies were worth $921,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new stake in shares of Agilent Technologies in the 4th quarter worth approximately $26,000. Crewe Advisors LLC boosted its position in shares of Agilent Technologies by 114.8% in the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Ridgewood Investments LLC bought a new stake in shares of Agilent Technologies in the 2nd quarter worth approximately $29,000. Rise Advisors LLC boosted its position in shares of Agilent Technologies by 527.8% in the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock worth $33,000 after purchasing an additional 190 shares in the last quarter. Finally, YHB Investment Advisors Inc. bought a new stake in shares of Agilent Technologies in the 1st quarter worth approximately $34,000. 87.42% of the stock is owned by institutional investors.

Insider Transactions at Agilent Technologies

In other news, CEO Padraig Mcdonnell sold 1,958 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the completion of the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at approximately $3,497,110. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is currently owned by company insiders.

Agilent Technologies Price Performance

Shares of A opened at $139.01 on Thursday. The firm has a market cap of $40.56 billion, a PE ratio of 32.86, a P/E/G ratio of 6.43 and a beta of 1.05. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. The firm has a fifty day simple moving average of $137.50 and a two-hundred day simple moving average of $139.25. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $155.35.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 21st. The medical research company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a return on equity of 25.26% and a net margin of 21.75%. Agilent Technologies’s revenue was down 5.6% on a year-over-year basis. During the same period in the prior year, the business posted $1.43 EPS. On average, equities analysts anticipate that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Wall Street Analysts Forecast Growth

A has been the topic of a number of analyst reports. Wells Fargo & Company initiated coverage on Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. Barclays upped their price objective on Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research report on Friday, August 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $151.00 price objective on shares of Agilent Technologies in a research report on Monday, August 26th. UBS Group upped their price objective on Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Finally, Bank of America upped their price objective on Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $141.60.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.